OSR Health is a post-combination healthcare holdco whose public listing is now the binding constraint on every other claim in the story. Nasdaq staff determined in mid-August that the common and the redeemable warrants failed the one-dollar bid-price test after two full compliance windows, and trading on that exchange was suspended at the open on August twenty-sixth. A Hearings Panel date sits at the end of September, which stays a formal Form twenty-five removal but does not put the tape back on the Capital Market. The residual equity therefore trades as an over-the-counter claim on a related-party license of VXM01, an oral VEGFR-two cancer immunotherapy, rather than as a funded clinical-stage operator.
The operating print underneath that listing fight is a shrinking Korean device-distribution line asked to carry a public-company cost base. Second-quarter net sales fell to $316 thousand as RMC, the neurovascular distributor, moved from purchase-and-resale to a consignment commission. Gross margin widened because the old model had booked a cost-basis inventory giveback a year earlier, not because a new franchise appeared. Cash at mid-year was $1.5 million against a first-half operating cash use of about $3.4 million, so the White Lion equity line and a small secured convertible note are what keep the lights on. The April license with BCM Europe, the largest holder, advertises up to $815 million of milestones. That cash is not in the bank. Those amounts are promises from a related party that also pledged its own OSRH stock as collateral.
The investment debate is whether any of that license option survives a lost listing, continued equity-line issuance, and a capital stack that cannot fund the research program the story is sold on. Management has already said research spending has not been incurred in size because financing is scarce. A restored listing plus a funded Phase Two path at Vaximm would give the residual claim something to attach to. A denied appeal plus another quarter of equity-line draws would leave holders with a thin cash account, a large intangible book, and a licensee that is also the controlling economic counterparty. The next test is the Panel, not another quarter of commission revenue.